REGN Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

Open

VWAP

Vol

Mkt Cap

70.90B

Low

Amount

EV/EBITDA(TTM)

13.63

Total Shares

104.84M

62.08B

EV/OCF(TTM)

12.38

P/S(TTM)

4.70

Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Lynozyfic, and others.

Events Timeline

(ET)

2026-06-29

17:00:00

FDA Selects Seven Companies for PreCheck Pilot Program

2026-06-29

16:30:00

Major Averages Finish Broadly Higher as Investors Await Middle East News

2026-06-29

15:00:00

FDA Announces First Companies in PreCheck Pilot Program

2026-06-22 (ET)

2026-06-22

07:30:00

Regeneron's Cemdisiran Accepted by FDA and EMA

2026-06-22

06:30:00

Wells Fargo Raises AbbVie Price Target to $260

News

9.5

07-06seekingalpha

PinnedRegeneron Projects $127M R&D Charge for Q2 2026

9.5

07-02Fool

Alnylam Pharmaceuticals Shares Drop 24%, Yet Optimism Persists

9.5

07-02NASDAQ.COM

Alnylam Pharmaceuticals Reports Strong Q1 Performance

9.5

07-01Fool

Intellia Therapeutics Shares Surge 83% Amid Strong Clinical Progress

7.0

06-30Newsfilter

Supreme Court Rulings Have Significant Implications

7.0

06-30CNBC

Supreme Court Rulings Have Far-Reaching Implications

22 Analyst Rating

Wall Street analysts forecast REGN stock price to rise

16 Buy

6 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

637.00

Averages

808.50

High

1057

Current: 0.000

Low

637.00

Averages

808.50

High

1057

Truist

Buy

maintain

$778 -> $769

AI Analysis

2026-07-07

New

Reason

Truist

Price Target

$778 -> $769

AI Analysis

2026-07-07

New

maintain

Buy

Reason

Truist lowered the firm's price target on Regeneron to $769 from $778 and keeps a Buy rating on the shares as part of a broader research note previewing Q2 earnings in Biotech. The firm is anticipating a rebound from a traditionally softer start to the year, with strength in Q2 prints for commercial franchises within its coverage, the analyst tells investors in a research note. Truist adds that it sees a robust catalyst calendar, supported by sector optimism and deal activity, as drivers for the recent momentum across the sector.

RBC Capital

Sector Perform

downgrade

$707 -> $696

2026-07-07

New

Reason

RBC Capital

Price Target

$707 -> $696

2026-07-07

New

downgrade

Sector Perform

Reason

RBC Capital lowered the firm's price target on Regeneron to $696 from $707 and keeps a Sector Perform rating on the shares as part of a broader research note previewing Q2 earnings in Biotech. The biotech sector has picked up considerable momentum, with a near-unprecedented two-week move in June relative to the S&P - driven by strong data expanding innovative spaces and perceptions around improving FDA flexibility/stability - and with outlooks more concretely definable than other high-volatility spaces, capital could continue to flow in, the analyst tells investors in a research note. Q2 earnings are shaping up to be seasonally strong, and with multiple opportunities for beats and the M&A resurgence likely to continue, there is little that would materially derail things, the firm added.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for REGN

Unlock Now

Valuation Metrics

The current forward P/E ratio for Regeneron Pharmaceuticals Inc (REGN.O) is 14.58, compared to its 5-year average forward P/E of 16.77. For a more detailed relative valuation and DCF analysis to assess Regeneron Pharmaceuticals Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

16.77

Current PE

14.58

Overvalued PE

19.88

Undervalued PE

13.66

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

11.90

Current EV/EBITDA

16.29

Overvalued EV/EBITDA

14.68

Undervalued EV/EBITDA

9.11

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

5.74

Current PS

3.88

Overvalued PS

6.88

Undervalued PS

4.59

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

then do u have other alternative stock

Intellectia · 8 candidates

Market Cap: >= 5.00BThemes: BiotechAnalyst Consensus: Moderate Buy, Strong BuyMoving Average Relationship: PriceAboveMA200Is Optionable: True

Ticker

Name

Market Cap$

AMGN

Amgen Inc

181.47B

GILD

Gilead Sciences, Inc

160.88B

VRTX

Vertex Pharmaceuticals Inc

110.90B

REGN

Regeneron Pharmaceuticals Inc

73.20B

BIIB

Biogen Inc

28.49B

INCY

Incyte Corp

19.04B

find me the best stocks for free

Intellectia · 20 candidates

Net Margin: >= 10.00Revenue 5yr Cagr: >= 5Eps 5yr Cagr: >= 5Pe Ttm: 5 - 30P/B Ratio: <= 5.00Return On Equity: >= 12.0%Moving Average Relationship: PriceAboveMA200Is Index Component: GSPC

Ticker

Name

Market Cap$

Goldman Sachs Group Inc

238.24B

NEE

Nextera Energy Inc

191.79B

Chubb Limited

127.24B

NEM

Newmont Corporation

111.36B

CME

CME Group Inc

107.96B

PNC

PNC Financial Services Group Inc

81.34B

top stocks in health sector

Intellectia · 38 candidates

Market Cap: >= 10.00BSector: Healthcare, Healthcare Services & EquipmentIndustry: Biotechnology & Medical Research, Healthcare Equipment & Supplies, Healthcare Providers & Services, PharmaceuticalsAnalyst Consensus: Strong Buy, Moderate BuyRevenue 5yr Cagr: >= 5List Exchange: XNYS, XNAS, XASEReturn On Equity: >= 10.0%

Ticker

Name

Market Cap$

LLY

Eli Lilly and Co

866.87B

ABBV

AbbVie Inc

364.65B

AZN

AstraZeneca PLC

293.00B

MRK

Merck & Co Inc

282.35B

UNH

UnitedHealth Group Inc

254.55B

AMGN

Amgen Inc

188.63B

what stock should I buy today

Intellectia · 52 candidates

Pe Ttm: 12 - 30Return On Equity: >= 15.0%Moving Average Relationship: PriceAboveMA20, PriceAboveMA200Is Index Component: GSPC

Ticker

Name

Market Cap$

JNJ

Johnson & Johnson

573.51B

Micron Technology Inc

519.64B

Coca-Cola Co

333.92B

CSCO

Cisco Systems Inc

313.11B

MRK

Merck & Co Inc

286.48B

LIN

Linde PLC

228.94B

how to use AI screener

Intellectia · 74 candidates

Market Cap: >= 10.00BRevenue 5yr Cagr: >= 8Pe Ttm: 10 - 25Return On Equity: >= 15.0%Monthly Average Dollar Volume: >= 2,000,000

Ticker

Name

Market Cap$

JPM

JPMorgan Chase & Co

764.45B

MRK

Merck & Co Inc

285.83B

Morgan Stanley

245.91B

Royal Bank of Canada

225.22B

NVO

Novo Nordisk A/S

169.49B

SCHW

Charles Schwab Corp

163.06B

what to buy or sell now

Intellectia · 39 candidates

Market Cap: >= 20.00BRevenue 5yr Cagr: >= 8Pe Ttm: 12 - 30Moving Average Relationship: PriceAboveMA200Is Index Component: GSPC, NDX, DJI

Ticker

Name

Market Cap$

XOM

Exxon Mobil Corp

639.72B

CMI

Cummins Inc

74.44B

HAL

Halliburton Co

29.18B

NEM

Newmont Corporation

124.54B

AEE

Ameren Corp

30.41B

REGN

Regeneron Pharmaceuticals Inc

78.93B

give me a selection of long term stocks

Intellectia · 27 candidates

Market Cap: >= 50.00BRevenue 5yr Cagr: >= 8Pe Ttm: 12 - 30Return On Equity: >= 13.0%Is Index Component: GSPC

Ticker

Name

Market Cap$

Whales Holding REGN

Armistice Capital LLC

Applied Finance Advisors, LLC

ARS Investment Partners, LLC

Greenwich Wealth Management, LLC

Gotham Asset Management, LLC

Trading Trends

People Also Watch

Frequently Asked Questions

What is Regeneron Pharmaceuticals Inc (REGN) stock price today?

The current price of REGN is 0 USD — it has increased 0

What is Regeneron Pharmaceuticals Inc (REGN)'s business?

What is the price predicton of REGN Stock?

Wall Street analysts forecast REGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for REGN is808.50 USD with a low forecast of 637.00 USD and a high forecast of 1057 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.